Trizivir
Sponsors
GlaxoSmithKline, International Antiviral Therapy Evaluation Center, National Institute of Allergy and Infectious Diseases (NIAID), Rijnstate Hospital, St. Luke's-Roosevelt Hospital Center
Conditions
HIVHIV InfectionHIV InfectionsInfection, Human Immunodeficiency Virus I
Phase 2
Phase 3
Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR
CompletedNCT00043888
Start: 2002-01-31End: 2003-05-31Target: 60Updated: 2013-02-12
FREE Study: Efficacy and Toxicity of Trizivir
CompletedNCT00405925
Start: 2003-03-31End: 2009-09-30Updated: 2010-06-02
Phase 4
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
CompletedNCT00082394
Start: 2004-04-26End: 2006-03-01Updated: 2017-05-24
2NN & CHARM Long-Term Follow-up Study
CompletedNCT00127972
Start: 2004-02-29End: 2007-04-30Updated: 2007-04-30
Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults
CompletedNCT00449436
Start: 2005-01-10End: 2007-12-13Updated: 2018-10-15
Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects
CompletedNCT00960622
Start: 2006-08-31End: 2009-07-31Updated: 2013-03-04